Funds & ETFs 

Jupiter European seeks global growth

This fund is run is run by Alexander Darwall, who takes a bottom-up, and blunt, approach to investing: "We invest in specific investment opportunities rather than simply in lazy macroeconomic assumptions," he says in his latest fund commentary. "We remain confident that our investment approach is an appropriate one for current circumstances."

That said, the fund is almost entirely invested in Northern Europe, with just over 3 per cent of its assets in Ireland and Spain. However, Mr Darwall says this is not because of testing macroeconomic problems in southern Europe, but rather he cannot find the types of companies he wants listed there.

He favours companies that depend on their own efforts rather than factors beyond their own control, whose products are in universal demand and not especially price sensitive. Examples include top 10 holding Novo Nordisk, which is listed in Denmark but sells diabetes treatments globally. Although the fund buys companies listed in Europe, it seeks gain from ones that benefit from global growth including in developing economies.

Mr Darwall tries to position the portfolio to do well in a range of circumstances. To this end, he seeks companies with strong balance sheets which make productivity-enhancing and cost-saving products and services. He also wants them to demonstrate good profitability, a proven business model, evidence of entrepreneurial endeavour and above-average growth opportunities.

He runs a concentrated portfolio of companies able to sustain profit growth and margins over a long period of time, as his focus is long-term performance rather than a short-term bounce.

JUPITER EUROPEAN (EASCA)

PRICE (NAV)952.9pSHARPE RATIO0.41
SIZE OF FUND£1.59bn1 YR PERFORMANCE21.32%
No OF HOLDINGS40*3 YR PERFORMANCE9.43%
SET UP DATE3-Aug-87*5 YR PERFORMANCE11.37%
MANAGER START DATE01-Jan-01TOTAL EXPENSE RATIO1.81%
FEESInitial 5%, annual 1.5%YIELD0.33%
BETA0.69MINIMUM INVESTMENT£500
STANDARD DEVIATION24.4MORE DETAILSwww.jupiteronline.co.uk

Source: Morningstar, *Theadneedle

Performance data as at 6 January 2010.

Top ten holdings as at 30 November 2010

HoldingPercentage
Novozymes7.94
Novo Nordisk7.7
Sygenta5.64
DnB NOR5.42
Neopost5.31
Vopak4.45
Reed Elsevier4.3
Fresenius3.96
Modern Times3.71
Schneider Electric3.61

Geographic breakdown

CountryPercentage
France22.95
Denmark17.31
Germany16.67
Netherlands10.86
Switzerland10.07
Norway9.37
Sweden7.09
United Kingdom2.44
Ireland1.77
Spain1.31
Cash0.16

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now